Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BAY3283142 in Participants With Mild to Moderate Arterial Hypertension
NCT06428825Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BAY3283142 in hypertension (HTN) (4 arms), sponsored by Bayer. Primary endpoint: Number of participants with treatment-emergent adverse events. Started Aug 2024; status: completed.
02
Drugs
BAY3283142
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06428825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428825.